^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADCT-212

    i
    Other names: ADCT-212, ADCT212, ADCT 212
    Company:
    ADC Therapeutics
    Drug class:
    DNA replication inhibitor, PSMA-targeted antibody-drug conjugate
    Related drugs:
    1year
    Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers (AACR 2023)
    ADCT-212 was tolerated as a single 20 mg/kg dose in male rats, with exposure data being indicative of a linear PK profile with a half-life of approximately 12 days. In conclusion, ADCT-212 demonstrated potent and specific in vitro and in vivo anti-tumor activity while it was stable and well tolerated in the rat, warranting further development of ADCT-212 into the clinic.
    Preclinical
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 positive
    |
    ADCT-212 • SG 2000